• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/3/22 2:10:40 PM ET
    $ADAP
    $AVTX
    $CRIS
    $NERV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAP alert in real time by email

     

    Gainers

    • Turning Point (NASDAQ:TPTX) shares rose 116.6% to $74.0 during Friday's regular session. As of 13:30 EST, Turning Point's stock is trading at a volume of 22.4 million, which is 3412.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.6 billion.
    • Curis (NASDAQ:CRIS) stock increased by 27.28% to $1.03. As of 13:30 EST, this security is trading at a volume of 8.8 million shares, making up 360.3% of its average full-day volume over the last 100 days. The company's market cap stands at $94.4 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock increased by 25.4% to $0.39. The current volume of 1.6 million shares is 387.9% of Avalo Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $43.9 million.
    • Yumanity Therapeutics (NASDAQ:YMTX) shares moved upwards by 24.52% to $1.32. Trading volume for this security as of 13:30 EST is 205.1K, which is 46.7% of its average full-day volume over the last 100 days. The company's market cap stands at $14.3 million.
    • Rubius Therapeutics (NASDAQ:RUBY) stock rose 23.21% to $1.14. Trading volume for this security as of 13:30 EST is 1.0 million, which is 68.4% of its average full-day volume over the last 100 days. The company's market cap stands at $102.8 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares rose 22.02% to $1.75. As of 13:30 EST, Adaptimmune Therapeutics's stock is trading at a volume of 1.3 million, which is 150.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $282.7 million.

    Losers

    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 36.2% to $0.38 during Friday's regular session. Trading volume for this security as of 13:30 EST is 4.3 million, which is 289.1% of its average full-day volume over the last 100 days. The company's market cap stands at $10.7 million.
    • Rallybio (NASDAQ:RLYB) shares fell 29.41% to $9.34. Trading volume for this security as of 13:30 EST is 324.6K, which is 256.2% of its average full-day volume over the last 100 days. The company's market cap stands at $300.1 million.
    • Novavax (NASDAQ:NVAX) shares fell 22.38% to $43.45. The current volume of 15.0 million shares is 322.1% of Novavax's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $3.3 billion.
    • Bright Green (NASDAQ:BGXX) stock decreased by 20.7% to $2.85. Trading volume for this security as of 13:30 EST is 2.7 million, which is 73.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $452.1 million.
    • Minerva Neurosciences (NASDAQ:NERV) shares fell 19.89% to $0.34. As of 13:30 EST, Minerva Neurosciences's stock is trading at a volume of 1.7 million, which is 1873.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.4 million.
    • Zosano Pharma (NASDAQ:ZSAN) shares decreased by 19.03% to $0.81. As of 13:30 EST, Zosano Pharma's stock is trading at a volume of 897.3K, which is 9.6% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $AVTX
    $CRIS
    $NERV

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    Novavax Inc.
    $NVAX
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADAP
    $AVTX
    $CRIS
    $NERV
    SEC Filings

    View All

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:20:33 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:15:07 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:15:32 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bartoszek Raymond J. bought $9,950 worth of shares (2,250 units at $4.42), increasing direct ownership by 15% to 17,206 units (SEC Form 4)

    4 - KINETA, INC./DE (0001445283) (Issuer)

    12/6/23 6:21:27 PM ET
    $YMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Philips Craig W. bought $9,812 worth of shares (3,000 units at $3.27), increasing direct ownership by 5% to 60,811 units (SEC Form 4)

    4 - KINETA, INC./DE (0001445283) (Issuer)

    11/30/23 5:27:11 PM ET
    $YMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

    BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ETWebcast:https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU   If you are interested in meeting with the Minerva team during the conference, please reach

    3/4/26 7:00:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

    Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (NASDAQ:RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into

    3/2/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that it will participate in the following upcoming investor conferences:TD Cowen 46th Annual Health Care Conference:Fireside ChatDate:Tuesday, March 3, 2026Time:2:30 p.m. Eastern Time (ET)Location:Boston, MALeerink Partners 2026 Global Healthcare Conference:Fireside ChatDate:Tuesday, March 10, 2026Time:3:40 p.m. ETLocation:Miami Beach, FLJefferies Biotech on the Beach Summit:Investor MeetingsDate:Wednesday, March 11, 2026Location:Miami Beach, FLA webcast of the fireside chats will be available through the Events and Presentations page of the Company's website at ir.novavax.com. A replay of each webc

    2/26/26 4:30:00 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fmr Llc claimed ownership of 211,798 shares (SEC Form 3)

    3 - Rallybio Corp (0001739410) (Issuer)

    3/10/26 1:24:15 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 5% to 130,599 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:13:36 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Kelly James Patrick

    4/A - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:12:20 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Novavax with a new price target

    Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00

    10/24/25 8:05:21 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

    SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 12:05:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AVTX
    $CRIS
    $NERV
    Financials

    Live finance-specific insights

    View All

    Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

    Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (NASDAQ:RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into

    3/2/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care